Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT00519896
Show Display Options
Rank Status Study
1 Active, not recruiting Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Conditions: Recurrent Thyroid Cancer;   Stage IVA Follicular Thyroid Cancer;   Stage IVA Papillary Thyroid Cancer;   Stage IVB Follicular Thyroid Cancer;   Stage IVB Papillary Thyroid Cancer;   Stage IVC Follicular Thyroid Cancer;   Stage IVC Papillary Thyroid Cancer;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: sunitinib malate;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years